Mark O'Hara
Abramson Cancer Center, University of Pennsylvania · University of Pennsylvania · Abramson Cancer Center at Penn Medicine
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Mark O'Hara as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:28 UTC. Open this list on ClinicalTrials.gov
- N/ANCT05743049 · Collection of Circulating Biomarkers in Pancreatic CancerAbramson Cancer Center at Penn Medicine · recruiting · Pancreas Cancer · principal investigator
- Ph1NCT05484011 · A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal AdenocarcinomaHiberCell, Inc. · terminated · Metastatic Pancreatic Adenocarcinoma · study chair
- Ph2NCT05297903 · XmAb20717 in Advanced Biliary Tract CancersAbramson Cancer Center at Penn Medicine · completed · Biliary Tract Cancer · principal investigator
- Ph1NCT03592888 · DC Vaccine in Pancreatic CancerUniversity of Pennsylvania · completed · Pancreatic Ductal Adenocarcinoma · principal investigator
- Ph1NCT03323944 · CAR T Cell Immunotherapy for Pancreatic CancerUniversity of Pennsylvania · terminated · Pancreatic Cancer, Cancer of the Pancreas · principal investigator
- N/ANCT02907086 · Circulating Tumor Material in Colorectal Cancer and MelanomaAbramson Cancer Center at Penn Medicine · completed · Colorectal Cancer and Melanoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:28 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in pancreatic cancer, ranked by citations from NIH iCite, fetched 2026-11-12 12:28 UTC. The ranking covers the 200 most relevant of 12 PubMed records, and a shared surname and initials can bring in a namesake. All 12 on PubMed
- Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial.Gastroenterology · 2018439 citationsRCR 13.0
- 329 citationsRCR 19.5
- 266 citationsRCR 9.4
- 260 citationsRCR 12.8
- 222 citationsRCR 10.8
- Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer.Clin Cancer Res · 2021172 citationsRCR 8.0
- Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial.Lancet Oncol · 2022141 citationsRCR 8.0
- 28 citationsRCR 5.0
- A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer.Cancer Chemother Pharmacol · 201810 citationsRCR 0.4
- Concurrent Nab-paclitaxel and Radiotherapy: Novel Radiosensitization for Borderline Resectable or Unresectable Pancreatic Cancer.Am J Clin Oncol · 20218 citationsRCR 0.5